229 related articles for article (PubMed ID: 20690888)
1. Emerging drugs for high-grade osteosarcoma.
Hattinger CM; Pasello M; Ferrari S; Picci P; Serra M
Expert Opin Emerg Drugs; 2010 Dec; 15(4):615-34. PubMed ID: 20690888
[TBL] [Abstract][Full Text] [Related]
2. Advances in emerging drugs for osteosarcoma.
Hattinger CM; Fanelli M; Tavanti E; Vella S; Ferrari S; Picci P; Serra M
Expert Opin Emerg Drugs; 2015 Sep; 20(3):495-514. PubMed ID: 26021401
[TBL] [Abstract][Full Text] [Related]
3. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
Hattinger CM; Serra M
Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
Sun J; Fu ZM; Fang CQ; Li JH
Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
[TBL] [Abstract][Full Text] [Related]
5. Preliminary study of chemosenstivity tests in osteosarcoma using a histoculture drug response assay.
Lee SY; Jeon DG; Cho WH; Song WS; Kim MB; Park JH
Anticancer Res; 2006; 26(4B):2929-32. PubMed ID: 16886615
[TBL] [Abstract][Full Text] [Related]
6. Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics.
Kikuta K; Tochigi N; Saito S; Shimoda T; Morioka H; Toyama Y; Hosono A; Suehara Y; Beppu Y; Kawai A; Hirohashi S; Kondo T
Proteomics Clin Appl; 2010 May; 4(5):560-7. PubMed ID: 21137073
[TBL] [Abstract][Full Text] [Related]
7. [Osteogenic osteosarcoma and drug therapy. Study in vitro of osteosarcoma's sensitivity to drugs. Therapeutic applications].
Morasca L; Roy-Camille R; Pouliquen JC
Chirurgie; 1970; 96(1):53-62. PubMed ID: 5279883
[No Abstract] [Full Text] [Related]
8. Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients.
Pratt CB; Epelman S; Jaffe N
Cancer Treat Rep; 1987 Apr; 71(4):421-3. PubMed ID: 2435408
[No Abstract] [Full Text] [Related]
9. [Human tumor clonogenic assay in osteosarcoma and its clinical evaluation].
Tomita K; Yokogawa A; Nomura S
Gan To Kagaku Ryoho; 1986 May; 13(5):1876-80. PubMed ID: 3458429
[TBL] [Abstract][Full Text] [Related]
10. [Goal and results of the COSS study].
Flege S; Bielack S
Handchir Mikrochir Plast Chir; 2004 Oct; 36(5):282-8. PubMed ID: 15503258
[TBL] [Abstract][Full Text] [Related]
11. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
12. [Pathologic anatomy of osteosarcoma in children and adolescents. Diagnostic considerations].
Costa J; Contesso G; Remagen W
Chir Pediatr; 1985; 26(4):226-32. PubMed ID: 3907872
[No Abstract] [Full Text] [Related]
13. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series.
Müller CR; Smeland S; Bauer HC; Saeter G; Strander H
Acta Oncol; 2005; 44(5):475-80. PubMed ID: 16118081
[TBL] [Abstract][Full Text] [Related]
14. Metastatic osteosarcoma.
Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
[TBL] [Abstract][Full Text] [Related]
15. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.
Mohseny AB; Szuhai K; Romeo S; Buddingh EP; Briaire-de Bruijn I; de Jong D; van Pel M; Cleton-Jansen AM; Hogendoorn PC
J Pathol; 2009 Nov; 219(3):294-305. PubMed ID: 19718709
[TBL] [Abstract][Full Text] [Related]
16. Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.
Li S; Sun W; Wang H; Zuo D; Hua Y; Cai Z
Tumour Biol; 2015 Mar; 36(3):1329-38. PubMed ID: 25666750
[TBL] [Abstract][Full Text] [Related]
17. [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors].
Salzer-Kuntschik M; Brand G; Delling G
Pathologe; 1983 May; 4(3):135-41. PubMed ID: 6576329
[No Abstract] [Full Text] [Related]
18. Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome.
Hicks MJ; Roth JR; Kozinetz CA; Wang LL
J Clin Oncol; 2007 Feb; 25(4):370-5. PubMed ID: 17264332
[TBL] [Abstract][Full Text] [Related]
19. [Cis-dichlorodiammineplatinum in osteosarcoma. Osteosarcoma Cooperative Study Group report].
Fukuma H; Beppu Y; Chuman H; Yagi T; Yamawaki S; Isu K; Funayama K; Tanuma M; Abe Y; Toriyama S
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):811-7. PubMed ID: 2653222
[TBL] [Abstract][Full Text] [Related]
20. [Use of carminomycin on children and adolescents with osteogenic sarcoma].
Bizer VA
Antibiotiki; 1979 Feb; 24(2):137-40. PubMed ID: 373620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
